Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239199 | 0.88 | TDP1 (0.65) | CYP4F2CYP4A11TDP1KDM4EALDH1A1 | |
| SCHEMBL80185 | 0.87 | CYP4A11 (0.58) | CYP4F2CYP4A11TP53BCL2 | |
| SCHEMBL3812842 | 0.86 | TDP1 (0.52) | CYP4F2CYP4A11TDP1KDM4EALDH1A1 | |
| SCHEMBL9490025 | 0.85 | TP53 (0.52) | TP53BCL2TRPA1MEN1KMT2A | |
| SCHEMBL9111608 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11 | |
| SCHEMBL13703310 | 0.84 | CYP4F2 (0.57) | CYP4F2CYP4A11 | |
| Hydrogen Peroxide SCHEMBL11520377 | 0.83 | TP53 (0.63) | MAPTTP53BCL2TRPA1MGLL | |
| Methyl Alcohol SCHEMBL28745884 | 0.83 | TP53 (0.55) | ALDH1A1MAPTTP53BCL2TRPA1 | |
| SCHEMBL26240023 | 0.83 | LPL (0.53) | CYP4F2CYP4A11TDP1 | |
| SCHEMBL166894 | 0.83 | TP53 (0.61) | ALDH1A1MAPTTP53BCL2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| EP-3906969-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | East China University of Science and Technology (CN) | 2021-11-10 | — | — | EP | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20150361095-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8530520-B2 | Cycloalkyl-dione derivatives and methods of their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120329877-A1 | Cycloalkyl-dione Derivatives And Methods Of Their Use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | CYP4F2 1184/4885CYP4A11 1518/4885TDP1 1100/4885 |
| US-20120329877-A1 | Cycloalkyl-dione Derivatives And Methods Of Their Use | CYP11B2, CYP1B1, SQLE | CYP4F2 250/4885CYP4A11 105/4885TDP1 1529/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CYP4F2 2482/4885CYP4A11 1183/4885TDP1 884/4885 |
| US-20150361095-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PIK3CD | CYP4F2 1980/4885CYP4A11 857/4885TDP1 1294/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | CYP4F2 1184/4885CYP4A11 1518/4885TDP1 1100/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CYP4F2 2605/4885CYP4A11 1204/4885TDP1 931/4885 |
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | CYP4F2 62/4885CYP4A11 39/4885TDP1 4262/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CYP4F2 69/4885CYP4A11 37/4885TDP1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.